Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:disease
|
| gptkbp:abbreviation |
HCV infection
|
| gptkbp:affectedPopulation |
humans
|
| gptkbp:affectsOrgan |
liver
|
| gptkbp:canBeAcute |
yes
|
| gptkbp:canBeAsymptomatic |
yes
|
| gptkbp:canBeChronic |
yes
|
| gptkbp:canBeCured |
yes, with modern antivirals
|
| gptkbp:cause |
end-stage liver disease
|
| gptkbp:causedBy |
gptkb:hepatitis_C_virus
|
| gptkbp:chronicInfectionRate |
~75-85% of cases
|
| gptkbp:complication |
liver cancer
cirrhosis liver failure |
| gptkbp:diagnosedBy |
HCV RNA test
blood test liver biopsy |
| gptkbp:firstDescribed |
1989
|
| gptkbp:gene |
genotype 1
genotype 2 genotype 3 genotype 4 genotype 5 genotype 6 |
| https://www.w3.org/2000/01/rdf-schema#label |
hepatitis C
|
| gptkbp:ICD-10_code |
B17.1
B18.2 |
| gptkbp:mortalityRate |
~290,000 deaths per year (2022, WHO)
|
| gptkbp:prevalence |
~58 million people (2022, WHO)
|
| gptkbp:prevention |
harm reduction for drug users
no vaccine available safe injection practices screening blood products |
| gptkbp:riskFactor |
HIV infection
blood transfusion before 1992 hemodialysis injecting drug use tattooing with unsterile equipment |
| gptkbp:symptom |
nausea
abdominal pain fatigue jaundice loss of appetite |
| gptkbp:transmissionRoute |
blood-to-blood contact
mother-to-child transmission sharing needles unsafe medical procedures |
| gptkbp:treatment |
gptkb:insulin
antiviral drug direct-acting antivirals ribavirin |
| gptkbp:bfsParent |
gptkb:Francisco_Varela
|
| gptkbp:bfsLayer |
4
|